These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 11983635)

  • 21. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
    Lenox-Smith AJ; Jiang Q
    Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of venlafaxine compared with tricyclic antidepressants in depressive disorder: a meta-analysis.
    van den Broek WW; Mulder PG; van Os E; Birkenhäger TK; Pluijms E; Bruijn JA
    J Psychopharmacol; 2009 Aug; 23(6):708-13. PubMed ID: 18562424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Venlafaxine and SSRI remission data revisited.
    Kavirajan H
    Br J Psychiatry; 2004 May; 184():452-3. PubMed ID: 15123513
    [No Abstract]   [Full Text] [Related]  

  • 24. Safety and tolerability of the new antidepressants.
    Nelson JC
    J Clin Psychiatry; 1997; 58 Suppl 6():26-31. PubMed ID: 9227670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Venlafaxine: a novel antidepressant that has a dual mechanism of action.
    Andrews JM; Ninan PT; Nemeroff CB
    Depression; 1996; 4(2):48-56. PubMed ID: 9160640
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression.
    Nulman I; Koren G; Rovet J; Barrera M; Pulver A; Streiner D; Feldman B
    Am J Psychiatry; 2012 Nov; 169(11):1165-74. PubMed ID: 23128923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care.
    Lenox-Smith AJ; Reynolds A
    Br J Gen Pract; 2003 Oct; 53(495):772-7. PubMed ID: 14601352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis.
    Furukawa TA; Cipriani A; Cowen PJ; Leucht S; Egger M; Salanti G
    Lancet Psychiatry; 2019 Jul; 6(7):601-609. PubMed ID: 31178367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression.
    Costa e Silva J
    J Clin Psychiatry; 1998 Jul; 59(7):352-7. PubMed ID: 9714263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential effects of venlafaxine in the treatment of major depressive disorder according to baseline severity.
    Schmitt AB; Bauer M; Volz HP; Moeller HJ; Jiang Q; Ninan PT; Loeschmann PA
    Eur Arch Psychiatry Clin Neurosci; 2009 Sep; 259(6):329-39. PubMed ID: 19255709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactions.
    Thase ME; Entsuah R; Cantillon M; Kornstein SG
    J Womens Health (Larchmt); 2005 Sep; 14(7):609-16. PubMed ID: 16181017
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: an open-label, uncontrolled study.
    Kaplan EM
    Clin Ther; 2002 Jul; 24(7):1194-200. PubMed ID: 12182262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Citalopram versus other anti-depressive agents for depression.
    Cipriani A; Purgato M; Furukawa TA; Trespidi C; Imperadore G; Signoretti A; Churchill R; Watanabe N; Barbui C
    Cochrane Database Syst Rev; 2012 Jul; 2012(7):CD006534. PubMed ID: 22786497
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medical resource use and cost of venlafaxine or tricyclic antidepressant therapy. Following selective serotonin reuptake inhibitor therapy for depression.
    Griffiths RI; Sullivan EM; Frank RG; Strauss MJ; Herbert RJ; Clouse J; Goldman HH
    Pharmacoeconomics; 1999 May; 15(5):495-505. PubMed ID: 10537966
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discontinuation rates for selective serotonin reuptake inhibitors and other second-generation antidepressants in outpatients with major depressive disorder: a systematic review and meta-analysis.
    Gartlehner G; Hansen RA; Carey TS; Lohr KN; Gaynes BN; Randolph LC
    Int Clin Psychopharmacol; 2005 Mar; 20(2):59-69. PubMed ID: 15729080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Duloxetine versus other anti-depressive agents for depression.
    Cipriani A; Koesters M; Furukawa TA; Nosè M; Purgato M; Omori IM; Trespidi C; Barbui C
    Cochrane Database Syst Rev; 2012 Oct; 10():CD006533. PubMed ID: 23076926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regarding "Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs".
    Koesters M; Becker T; Weinmann S
    Biol Psychiatry; 2009 Sep; 66(5):e7; authour reply e9-10. PubMed ID: 19520365
    [No Abstract]   [Full Text] [Related]  

  • 38. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.
    Anderson IM
    J Affect Disord; 2000 Apr; 58(1):19-36. PubMed ID: 10760555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.
    Bielski RJ; Ventura D; Chang CC
    J Clin Psychiatry; 2004 Sep; 65(9):1190-6. PubMed ID: 15367045
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Achieving remission from depression with venlafaxine and venlafaxine extended release: a literature review of comparative studies with selective serotonin reuptake inhibitors.
    Rudolph RL
    Acta Psychiatr Scand Suppl; 2002; (415):24-30. PubMed ID: 12492770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.